Doroshow, James H.

CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set

Reinhold, W. C., Sunshine, M., Liu, H., Varma, S., Kohn, K. W., Morris, J., Doroshow, J., & Pommier, Y. (2012) · Cancer Research

Gene expression and cancer classificationComputational Drug Discovery Methods

Cited by 887

The National Cancer Institute ALMANAC: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity

Holbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research

Computational Drug Discovery MethodsCancer Cells and Metastasis

Cited by 359

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology

Abaan, O. D., Polley, E. C., Davis, S. R., Zhu, Y. J., Bilke, S., Walker, R. L., Pineda, M., Gindin, Y., Jiang, Y., Reinhold, W. C., et al. (2013) · Cancer Research

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 288

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research

PARP inhibition in cancer therapyCancer therapeutics and mechanisms

Cited by 259

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

PDXNET Consortium, Woo, X. Y., EurOPDX Consortium, Giordano, J., Srivastava, A., Zhao, Z.-M., Lloyd, M. W., de Bruijn, R., Suh, Y.-S., Patidar, R., et al. (2021) · Nature Genetics

Cancer Genomics and DiagnosticsGenomic variations and chromosomal abnormalities

Cited by 190

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis)

Kummar, S., O'Sullivan Coyne, G., Do, K. T., Turkbey, B., Meltzer, P. S., Polley, E., Choyke, P. L., Meehan, R., Vilimas, R., Horneffer, Y., et al. (2017) · Journal of Clinical Oncology

Soft tissue tumor case studiesNeurofibromatosis and Schwannoma Cases

Cited by 183

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

Jeong, W., Rapisarda, A., Park, S. R., Kinders, R. J., Chen, A., Melillo, G., Turkbey, B., Steinberg, S. M., Choyke, P., Doroshow, J. H., et al. (2014) · Cancer Chemotherapy and Pharmacology

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 159

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors

Kummar, S., Raffeld, M., Juwara, L., Horneffer, Y., Strassberger, A., Allen, D., Steinberg, S. M., Rapisarda, A., Spencer, S. D., Figg, W. D., et al. (2011) · Clinical Cancer Research

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 115

Nox4 regulates InsP3 receptor‐dependent Ca2+ release into mitochondria to promote cell survival

Beretta, M., Santos, C. X., Molenaar, C., Hafstad, A. D., Miller, C. C., Revazian, A., Betteridge, K., Schröder, K., Streckfuß‐Bömeke, K., Doroshow, J. H., et al. (2020) · The EMBO Journal

Mitochondrial Function and PathologyCardiac Ischemia and Reperfusion

Cited by 93

United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies

Jeong, W., Doroshow, J. H., & Kummar, S. (2013) · Current Problems in Cancer

Heterocyclic Compound Synthesis and BioactivitySynthesis and Characterization of Heterocyclic Compounds

Cited by 59

Abstract 3616: Validation and fitness testing of a quantitative immunoassay for HIF1α in biopsy specimens

Park, S. R., Kinders, R. J., Khin, S., Hollingshead, M., Parchment, R. E., Tomaszewski, J. E., & Doroshow, J. H. (2012) · Cancer Research

Cancer, Hypoxia, and MetabolismClinical Laboratory Practices and Quality Control

Cited by 1